The post Bitcoin Underpeforming US Treasuries – U.Today appeared on BitcoinEthereumNews.com. In a truly shocking twist, Bitcoin has now performed worse than the U.S. Treasuries in 2025. BTC is now up by a mere 8% this year.  Why it’s a big deal  US Treasuries are typically known for being the ultimate risk-free benchmark for investors. Hence, the fact that the highly speculative asset performs worse than US Treasuries during what was supposed to be a banner year for crypto shows just how weak the cryptocurrency is.  It is worth noting that Bitcoin (the yellow line) did spend most of the year well above Treasuries. However, it dropped below them on Tuesday following the latest price crash that erased a significant portion of its 2025 gains.  As reported by U.Today, the flagship coin recently briefly dropped below the $100,000 level.  “Max desperation”  According to Matt Hougan, Bitwise’s chief investment officer, has noted that retail investors are at the point of “max desperation.”  However, Hougan is convinced that another cryptocurrency winter is not coming.  Key level to watch On Tuesday, Bitcoin exchange-traded funds (ETFs) logged a whopping $578 worth of outflows.  Notably, the average cost basis of all Bitcoins ever bought through spot ETFS currently stands $89,600.  Source: https://u.today/bitcoin-underpeforming-us-treasuriesThe post Bitcoin Underpeforming US Treasuries – U.Today appeared on BitcoinEthereumNews.com. In a truly shocking twist, Bitcoin has now performed worse than the U.S. Treasuries in 2025. BTC is now up by a mere 8% this year.  Why it’s a big deal  US Treasuries are typically known for being the ultimate risk-free benchmark for investors. Hence, the fact that the highly speculative asset performs worse than US Treasuries during what was supposed to be a banner year for crypto shows just how weak the cryptocurrency is.  It is worth noting that Bitcoin (the yellow line) did spend most of the year well above Treasuries. However, it dropped below them on Tuesday following the latest price crash that erased a significant portion of its 2025 gains.  As reported by U.Today, the flagship coin recently briefly dropped below the $100,000 level.  “Max desperation”  According to Matt Hougan, Bitwise’s chief investment officer, has noted that retail investors are at the point of “max desperation.”  However, Hougan is convinced that another cryptocurrency winter is not coming.  Key level to watch On Tuesday, Bitcoin exchange-traded funds (ETFs) logged a whopping $578 worth of outflows.  Notably, the average cost basis of all Bitcoins ever bought through spot ETFS currently stands $89,600.  Source: https://u.today/bitcoin-underpeforming-us-treasuries

Bitcoin Underpeforming US Treasuries – U.Today

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

In a truly shocking twist, Bitcoin has now performed worse than the U.S. Treasuries in 2025. BTC is now up by a mere 8% this year. 

Why it’s a big deal 

US Treasuries are typically known for being the ultimate risk-free benchmark for investors.

Hence, the fact that the highly speculative asset performs worse than US Treasuries during what was supposed to be a banner year for crypto shows just how weak the cryptocurrency is. 

It is worth noting that Bitcoin (the yellow line) did spend most of the year well above Treasuries. However, it dropped below them on Tuesday following the latest price crash that erased a significant portion of its 2025 gains. 

As reported by U.Today, the flagship coin recently briefly dropped below the $100,000 level. 

“Max desperation” 

According to Matt Hougan, Bitwise’s chief investment officer, has noted that retail investors are at the point of “max desperation.” 

However, Hougan is convinced that another cryptocurrency winter is not coming. 

Key level to watch

On Tuesday, Bitcoin exchange-traded funds (ETFs) logged a whopping $578 worth of outflows. 

Notably, the average cost basis of all Bitcoins ever bought through spot ETFS currently stands $89,600. 

Source: https://u.today/bitcoin-underpeforming-us-treasuries

Market Opportunity
Union Logo
Union Price(U)
$0.001055
$0.001055$0.001055
+3.53%
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09